Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
yongchang zhang, Ph.D.
CONTACT
Lead
MediLink Therapeutics (Suzhou) Co., Ltd.
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the advanced non small cell lung cancer/colorectal cancer/cervical cancer, etc. YL202 is an antibody-drug conjugate (ADC) that targets HER3 protein
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted